ライフサイエンスコーパス: Merck

1 xpressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck).

2 US, and Merck Sharp & Dohme, a subsidiary of Merck.

3 cer Institute, Novartis Pharmaceuticals, and Merck.

4 , Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

5 ssociated with higher levels of replication (Merck 035), but was not associated with virologic failur

6 ndinavir-zidovudine-lamivudine (ACTG 343 and Merck 035).

7 ected subjects enrolled in a clinical trial (Merck 039).

8 precolumn Chromolith Guard Cartridge RP-18e (Merck), 10x4.6mm, with a washing mobile phase (methanol:

9 f quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 years previously.

10 x (varicella virus vaccine live [Oka/Merck]; Merck), a live attenuated varicella vaccine, is indicate

11 University of New South Wales Australia, Merck, AbbVie, and the Foundation for AIDS Research.

12 li study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine

13 HDM sublingual immunotherapy tablet MK-8237 (Merck/ALK-Abello) using the Vienna Challenge Chamber.

14 s SLIT-tablet MK-7243 (2800 BAU/75 000 SQ-T, Merck/ALK-Abello) were pooled for post hoc analyses.

15 and Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.

16 Merck Sharp & Dohme, a subsidiary of Merck & Co.

17 est datasets of 74 patients from multicenter Merck and American College of Radiology Imaging Network

18 est datasets of 74 patients from multicenter Merck and American College of Radiology Imaging Network

19 Merck and Co, National Institutes of Health.

20 Eli Lilly and Company, and Merck and Co.

21 rch by laboratories in the nonprofit sector, Merck and GlaxoSmithKline are developing commercial vers

22 -type (Dumas) or vaccine VZV strains ((POka, Merck and GSK).

23 collaborative project by Purdue University, Merck and IMA Life develops the next generation of tunab

24 of ADK inhibitors that have been reported by Merck and Shionogi pharmaceutical companies, served as m

25 ur MHB sources (BD-BBL, BD-Difco, Oxoid, and Merck) and 85 Gram-negative isolates (Escherichia coli,

26 Merck Sharp & Dohme (a subsidiary of Merck) and Bayer.

27 e of licensed zoster vaccine (ZV) (Zostavax; Merck) and followed for occurrence of HZ for >/=1 year (

28 lyT1 inhibitors ALX-5407 (Allelix), (S)-13h (Merck), and SSR504734 (Sanofi-Synthelabo) were similar a

29 Cancer Research UK, Celgene, Amgen, Merck, and Myeloma UK.

30 nstitute of Allergy and Infectious Diseases, Merck, and South African Medical Research Council.

31 uated vaccines for gastroenteritis (Rotateq [Merck] and Rotarix) have been licensed in many countries

32 In addition to antibiotics, treatment with Merck anti-toxin B (TcdB) antibody bezlotoxumab is repor

33 ) were originally explored as antibiotics by Merck but failed in clinical trials due to unaccepted to

34 through CD11b/CD18 were strongly blocked by Merck C, an imidazole-based inhibitor of p38 mitogen-act

35 f p38 MAPK, but not ERK1/2, was inhibited by Merck C.

36 tional Heart, Lung, and Blood Institute; and Merck Childhood Asthma Network sponsored a joint worksho

37 ilent Zorbax SB300, Waters Symmetry 300, and Merck Chromolith.

38 SA) and Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA).

39 Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA).

40 Merck Sharp & Dohme, a subsidiary of Merck & Co (MSD).

41 Merck Sharp & Dohme Corp, a subsidiary of Merck & Co Inc, Kenilworth, NJ, USA.

42 of Haemophilus influenzae type B vaccines by Merck & Co Inc, Whitehouse Station, New Jersey, USA, the

43 Merck Sharp & Dohme (a subsidiary of Merck & Co) and the National Cancer Institute.

44 omen who received the HPV vaccine (Gardasil; Merck & Co) over a 12-year period following HPV vaccinat

45 Merck Sharpe & Dohme-Merck & Co, Canadian Cancer Society, Swiss Cancer League

46 Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc (Kenilworth, NJ, USA).

47 Merck Sharp & Dohme Corp (a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA).

48 Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA.

49 Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA, and Eisai, Nutley, NJ,

50 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA, and the National Cance

51 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA.

52 Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.

53 Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc.

54 ommercial nanoparticulate formulation EMEND (Merck & Co, Inc., Kenilworth, NJ, USA).

55 ng litigation related to rofecoxib involving Merck & Co, including internal company analyses and info

56 Merck & Co, Kenilworth, NJ, USA, in collaboration with m

57 eneca; Merck Sharpe & Dohme, a subsidiary of Merck & Co, Kenilworth, NJ, USA.

58 Merck Sharp & Dohme, a subsidiary of Merck & Co, Kenilworth, NJ, USA.

59 ingual immunotherapy (SLIT) tablet (MK-8237; Merck & Co, Kenilworth, NJ/ALK-Abello, Horsholm, Denmark

60 Merck Sharp & Dohme (a subsidiary of Merck & Co, NJ, USA), and Eisai.

61 Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.

62 on with Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.

63 Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA; the Intramural Research Pro

64 The Canadian Cancer Society and Merck & Co.

65 Merck Sharp & Dohme, a subsidiary of Merck & Co.

66 orking industrial scientists for 15 years at Merck & Co. and by similarly characterized students, pos

67 Merck & Co. and the National Heart, Lung, and Blood Inst

68 stribution of ivermectin - a drug donated by Merck & Co. for disease control in Africa and for diseas

69 l chemistry knowledge capture and sharing at Merck & Co. over the past 15 years.

70 measured, physiological effect of Claritin (Merck & Co.), a leading antihistamine medication, across

71 NGMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

72 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

73 Merck, Sharp, & Dohme Corp, a subsidiary of Merck & Co., Inc.

74 Merck & Co., Inc.

75 rcial fluorinated drug molecule developed by Merck & Co., Inc., Rahway, NJ, U.S.A., in its amorphous

76 E; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), a 15-valent pneumoc

77 valent recombinant vaccine, was developed by Merck & Co., Inc., Rahway, NJ, USA, and approved by the

78 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

79 y(A)-polymerase and were first discovered by Merck & Co., Inc., through a Candida albicans Fitness Te

80 erapy Research funds; Astex Pharmaceuticals; Merck & Co.; National Cancer Institute (NCI), NIH grants

81 chnology from DiscoveRx to screen the entire Merck compound library for glucocorticoid receptor (GR)

82 tion of human liver P450 3A4 by L-754,394, a Merck compound synthesized as a potential HIV protease i

83 tionship studies of compounds related to the Merck cyclic hexapeptide c[Pro6-Phe7-d-Trp8-Lys9-Thr10-P

84 rono SA-Geneva, Switzerland; an affiliate of Merck, Darmstadt, Germany.

85 In 1989, Larsen et al. at Merck discovered that the addition of chiral alcohols to

86 ext of addressing key questions posed by the Merck Discovery Chemistry community when considering a c

87 ccines (RV1 [Rotarix; GSK] and RV5 [RotaTeq; Merck]) diverge.

88 of the Jorgensen-Hayashi catalyst using the Merck dual acid cocatalyst system.

89 ical trials, documents were found describing Merck employees working either independently or in colla

90 nalysis of >1000 ESTs generated by the WashU-Merck EST project.

91 irus type 5 (Ad5)-based vaccine developed by Merck failed to either prevent HIV-1 infection or suppre

92 3 reports worldwide voluntarily submitted to Merck, for an overall reporting rate of 3.4 reports/10,0

93 Varivax is described using data submitted to Merck from routine global postmarketing surveillance, co

94 s is exemplified by the approval acquired by Merck from the US Food and Drug Administration (FDA) for

95 thacin or selective inhibition of COX-2 with Merck Frosst (MF) tricyclic, retards significantly ather

96 stralian Trade and Investment Commission and Merck Global Health Institute.

97 one of the most potent DKAs reported by the Merck group (L-708,906) and found that 5CITEP inhibits 3

98 Varicella vaccine (Varivax, Merck) has been available in the United States since 199

99 ccines being prepared by GlaxoSmithKline and Merck have completed large-scale clinical trials.

100 collection, analysis, and dissemination; and Merck hid the marketing nature of the trial from partici

101 V protease, monofluorinated analogues of the Merck HIV protease inhibitor indinavir, are described.

102 se of licensed zoster vaccine (ZV; Zostavax; Merck) in 50-59-year-olds showed approximately 70% vacci

103 vine reassortant rotavirus vaccine (RotaTeq; Merck) in developed countries have demonstrated that it

104 n antibiotic drug Cefoxitin sodium (Mefoxin; Merck Inc., West Point, PA) with high efficacy.

105 es assembled from common sources such as the Merck Index, pesticide and pharmaceutical compilations,

106 rticipate, including examples taken from the Merck Informer Library indicative of the functional grou

107 The NK-1R antagonist aprepitant (Emend, Merck) inhibited both the SP-induced Ca2+ increase in PM

108 Merck, International Breast Cancer Study Group.

109 ialization, Codexis and Schering-Plough (now Merck) jointly developed a chemoenzymatic asymmetric syn

110 Health Research, UK National Health Service, Merck, Julius Center for Health Sciences and Primary Car

111 Merck Sharp and Dohme, a subsidiary of Merck, Kenilworth, NJ, USA.

112 was provided by the health care business of Merck KGaA (Darmstadt, Germany), through a Cooperative R

113 Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).

114 Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).

115 National Institutes of Health, Merck KGaA, and Pfizer.

116 rancophone de Cancerologie Digestive (FFCD), Merck KGaA, and Sanofi-Aventis.

117 Here, screening 278 compounds from the Merck KGaA, Darmstadt, Germany collection and accelerate

118 Pfizer and Merck KGaA, Darmstadt, Germany.

119 Merck Serono SA Geneva, a subsidiary of Merck KGaA, Darmstadt, Germany.

120 Research Wales, UK Medical Research Council, Merck KGgA.

121 rate was also significantly enhanced by both Merck L7 alone and TLK16998 plus insulin.

122 Both TLK16998 and Merck L7 improved IR autophosphorylation in cells with d

123 bol acetate)-treated cells, TLK16998 but not Merck L7 was able to significantly reverse the impaired

124 (IR) beta-subunit tyrosine kinase activity: Merck L7, a direct IR agonist, and Telik's TLK16998, an

125 ilead Sciences, Janssen Pharmaceuticals, and Merck Laboratories.

126 S, Gilead Sciences, Janssen Pharmaceuticals, Merck Laboratories.

127 Merck, Leukemia and Lymphoma Society, National Institute

128 ohort, The University of Cologne HIV Cohort, Merck Life Sciences, ViiV Healthcare, and Gilead Science

129 Harrison's Textbook of Medicine, The Merck Manual, and Scientific American Medicine often men

130 view papers, documents were found describing Merck marketing employees developing plans for manuscrip

131 Varivax (varicella virus vaccine live [Oka/Merck]; Merck), a live attenuated varicella vaccine, is

132 al, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Pre

133 34 from the ACRIN 6678 trial and 40 from the Merck MK-0646-008 trial).

134 lar mechanics calculation approach using the Merck Molecular Force Field (MMFFs) was developed; this

135 mice with vehicle or with a GSI developed by Merck (MRK-003).

136 Cancer Research UK, Celgene, Amgen, Merck, Myeloma UK.

137 TLC determinations were similarly made using Merck NH2 F254S precoated glass plates (approximately 2

138 conversion rates, before and after 1 dose of Merck/Oka varicella vaccine.

139 y, Phenomenex, Hypersil, and Chromolith from Merck; one polymeric bonded phase, Vydac) with the same

140 Merck, Pfizer, American Cancer Society, and Sylvester Co

141 rs Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmace

142 We report composite results from the Merck phase I program of near-consensus clade B human im

143 columns (from Akzo Nobel, Bishoff, Hypersil, Merck, Phenomenex, Supelco, Vydac, and Waters) with seve

144 ths with: 1) vehicle; 2) AT(1)-ant (L158809, Merck, Rahway, New Jersey); 3) AT(1)-ant + AT(2)-ant (PD

145 irst human papillomavirus (HPV) vaccination (Merck, Rahway, NJ, USA) at week 4; and the HPV booster a

146 uadrivalent virus-like particle HPV vaccine (Merck, Rahway, NJ, USA) at week 4; and toxoid vaccines (

147 eca and Merck Sharp & Dohme, a subsidiary of Merck, Rahway, NJ, USA.

148 particle human papillomavirus (HPV) vaccine (Merck, Rahway, NJ, USA; 0.5 mL intramuscularly, left upp

149 5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study re

150 in support of a drug development program at Merck Research Laboratories.

151 The Merck rVSVDeltaG-ZEBOV-GP vaccine appeared to be safe an

152 ngle-arm cluster vaccination trial using the Merck rVSVDeltaG-ZEBOV-GP vaccine was initiated.

153 In this Perspective, examples from Merck's chemistry groups are used to highlight the types

154 a potent, highly selective CCR5 antagonist, Merck's compound 167 (CMPD 167), in an established cynom

155 cal trial articles published a disclosure of Merck's financial support, but only 50% (36 of 72) of re

156 An asymmetric total synthesis of Merck's hNK(1) antagonist and three of its stereoisomers

157 of equations were derived and implemented on Merck's intranet to score single sensorgrams to distingu

158 g division to fulfill a marketing objective; Merck's marketing division handled both the scientific a

159 aled 3 key themes: The trial was designed by Merck's marketing division to fulfill a marketing object

160 t ADVANTAGE was a seeding trial developed by Merck's marketing division to promote prescription of Vi

161 The key structural feature in Boceprevir, Merck's new drug treatment for hepatitis C, is the bicyc

162 However, Merck's nonavalent vaccine, produced via the Saccharomyc

163 Results from Merck's phase II adenovirus type 5 (Ad5) gag/pol/nef tes

164 Merck's Raltegravir (RAL) (October 2007) and Gilead's El

165 lly rhinoceros (Coelodonta antiquitatis) and Merck's rhinoceros (Stephanorhinus kirchbergensis).

166 ole (3) was identified from screening of the Merck sample collection as a human dopamine D4 (hD4) rec

167 versions, including (1) cortisone/cortisol (Merck/Sarett), (2) dendrobine (Kende), (3) vitamin B(12)

168 Merck/Schering-Plough Pharmaceuticals; Australian Nation

169 Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).

170 Merck Serono SA Geneva, a subsidiary of Merck KGaA, Darm

171 Merck Serono SA-Geneva, Switzerland; an affiliate of Mer

172 Scotland, and Northern Ireland, Biogen Idec, Merck Serono, Bayer Schering Pharmaceuticals, Teva Pharm

173 Council, European Research Council (335326), Merck Serono.

174 Merck Sharp & Dohme (a subsidiary of Merck & Co) and the

175 Merck Sharp & Dohme (a subsidiary of Merck & Co, NJ, USA

176 Merck Sharp & Dohme (a subsidiary of Merck) and Bayer.

177 Merck Sharp & Dohme and NanoString Technologies.

178 ional HbA1c Surveillance System [CNHSS]) and Merck Sharp & Dohme China (for the 3B study).

179 Merck Sharp & Dohme Corp (a subsidiary of Merck & Co, In

180 Oncoethix GmbH (a wholly owned subsidiary of Merck Sharp & Dohme Corp).

181 Merck Sharp & Dohme Corp, a subsidiary of Merck & Co Inc

182 Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, In

183 Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, In

184 Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.

185 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc

186 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc

187 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., In

188 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., In

189 Eisai (Nutley, NJ, USA) and Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilwo

190 Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilwo

191 Merck Sharp & Dohme, a subsidiary of Merck & Co (MSD).

192 Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc (Ke

193 Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc, Ra

194 Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc.

195 Merck Sharp & Dohme, a subsidiary of Merck & Co, Kenilwo

196 Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway,

197 Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway,

198 Moderna in collaboration with Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway,

199 Merck Sharp & Dohme, a subsidiary of Merck & Co.

200 part of an alliance between AstraZeneca and Merck Sharp & Dohme, a subsidiary of Merck, Rahway, NJ,

201 Eisai US, and Merck Sharp & Dohme, a subsidiary of Merck.

202 Ortho Biotech, Cancer Research UK, Celgene, Merck Sharp & Dohme, and Amgen.

203 Merck Sharp & Dohme, Biomedical Advanced Research and De

204 Belgium) or nine-valent vaccine (Gardasil-9; Merck Sharp & Dohme, Haarlem, Netherlands).

205 Merck Sharp & Dohme, National Institutes of Health, and

206 bVie, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme, ViiV Italy.

207 recipients of the 4-valent vaccine Gardasil (Merck Sharp & Dohme, Whitehouse Station, NJ, USA) from t

208 s of the quadrivalent HPV vaccine (Gardasil [Merck Sharp & Dohme, Whitehouse Station, NJ, USA]; 0.5 m

209 6 from an unknown source by researchers from Merck Sharp & Dohme.

210 earch Centres of Excellence initiatives, and Merck Sharp & Dohme.

211 llergy and Infectious Diseases (NIAID), NIH; Merck Sharp & Dohme.

212 Seagen, Astellas Pharma, and Merck Sharp & Dohme.

213 Stand Up to Cancer and Merck Sharp & Dohme.

214 Supported by AstraZeneca and Merck Sharp & Dohme.

215 iV Healthcare UK, Janssen Pharmaceutica, and Merck Sharp & Dohme.

216 Incyte Corporation, in collaboration with Merck Sharp & Dohme.

217 US National Cancer Institute, Merck Sharp & Dohme.

218 AstraZeneca and Merck Sharp & Dohme, a subsidiary of Merck & Co,

219 Merck Sharp & Dohme, a subsidiary of Merck & Co.

220 Merck Sharp and Dohme, a subsidiary of Merck, Kenilworth

221 nd Colitis UK, Cure Crohn's Colitis, AbbVie, Merck Sharp and Dohme, Napp Pharmaceuticals, Pfizer, and

222 My Duc Hospital and Merck Sharp and Dohme.

223 ety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of Merck & Co., I

224 Merck, Sharp, & Dohme Corp, a subsidiary of Merck & Co.,

225 AstraZeneca; Merck Sharpe & Dohme, a subsidiary of Merck & Co, Kenilw

226 Merck Sharpe & Dohme-Merck & Co, Canadian Cancer Society

227 A rigorous analysis of the Merck-sponsored EST data with respect to known gene sequ

228 pembrolizumab of 200 mg every 3 weeks in all Merck-sponsored trials.

229 ew articles published either a disclosure of Merck sponsorship or a disclosure of whether the author

230 The Merck STEP phase 2b efficacy trial of one such vaccine w

231 cts vaccinated with Ad5-HIV-1 vectors in the Merck STEP trial remain unclear.

232 alyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveilla

233 Merck; The Clinical Trial Service Unit also receives fun

234 The corresponding RCs from the Merck trial were -35% (95% CI, -42% to -29%) and +53% (9

235 or the ACRIN trial and 6.89 +/- 3.02 for the Merck trial.

236 parison group for HPV-16 (2393 vs 3892 milli-Merck units per milliliter [mMU/mL], P = .012) and HPV-1

237 er last vaccination for HPV-16 of 7736 milli-Merck units per mL (mMU/mL) (95% CI, 6651-8999) and HPV-

238 (geometric mean antibody titer = 53.9 milli-Merck units/ml, 95% CI, 34.8 to 83.7).

239 The Merck vaccine also targets HPV6 and HPV11, which account

240 n Mexico and the Dominican Republic, and the Merck vaccine could be licensed in the United States wit

241 After US licensure of the Merck varicella vaccine for immunocompetent persons on 1

242 The Oka/Merck varicella vaccine induces VZV immunity in elderly

243 ut the immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (h

244 ficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine.

245 ous Diseases, Boehringer Ingelheim, Janssen, Merck, ViiV Healthcare, Roche, and Monogram Biosciences

246 al of an investigational live attenuated Oka/Merck VZV vaccine ("zoster vaccine").

247 The Pregnancy Registry for Varivax (Merck) was established to monitor for congenital varicel

248 ion of expressed sequence tags (ESTs) by the Merck/WashU EST project.

249 Biologicals, Rixensart, Belgium) or RotaTeq (Merck, West Point, PA, USA), we included Rotarix and Rot

250 e-activated receptor-1 antagonist vorapaxar (Merck, Whitehouse Station, New Jersey) versus placebo am

251 he SP receptor antagonist aprepitant (Emend; Merck, Whitehouse Station, NJ) completely reversed the i

252 scrutiny because long-term rofecoxib (Vioxx; Merck, Whitehouse Station, NJ) treatment was found to in

253 lysin toxoid (psiPLY), Pneumovax 23 (PPSV23; Merck, Whitehouse Station, NJ), or phosphate-buffered sa